Oncimmune revenue falls as it implements new strategy
29th Feb 2024 13:04
(Sharecast News) - Oncimmune reported revenue of £2.1m in its final results on Thursday, down from £3.8m for the prior extended 15-month period, with revenue from continuing operations totalling £1.2m.
Read moreOncimmune sells 'non-core' lung and antibody assets in £13m deal
22nd May 2023 11:14
(Sharecast News) - Immunodiagnostics specialist Oncimmune announced the sale of its wholly-owned subsidiaries Oncimmune Limited and Oncimmune Europe to the US-based, privately-held Freenome Holdings on Monday.
Read moreOncimmune enters collaboration with Siemens Healthineers
17th Feb 2023 15:53
(Sharecast News) - Immunodiagnostics specialist Oncimmune announced a collaboration with Siemens Healthineers on Friday, to improve malignancy risk assessment of indeterminate pulmonary nodules (IPNs).
Read moreOncimmune agrees two new commercial contracts
8th Apr 2022 15:44
(Sharecast News) - Immunodiagnostics company Oncimmune announced the signing of two new commercial contracts for its 'ImmunoINSIGHTS' platform on Friday.
Read moreOncimmune signs new contract with Alphabet division Verily
28th Feb 2022 14:41
(Sharecast News) - Immunodiagnostics company Oncimmune Holdings announced the signing of a new commercial contract with Verily Life Sciences on Monday, a member of Google owner Alphabet's stable, focusing on the autoantibody profiling of patients who had Covid-19 and gone on to develop long lasting symptoms for more than four weeks, or 'long Covid'.
Read moreOncimmune's EarlyCDT Lung test granted approval by Ministry of Health for Aragon
17th Feb 2022 09:09
(Sharecast News) - Immunodiagnostics group Oncimmune Holdings said on Thursday that its EarlyCDT Lung test had been granted approval by the Ministry of Health for Aragon in Spain and will now be adopted in the University Hospital Miguel Servet in Zaragoza.
Read moreOncimmune reports fresh research from Cedars-Sinai Covid study
31st Dec 2021 11:20
(Sharecast News) - Oncimmune announced the publication of a paper arising from the research collaboration with Cedars-Sinai Medical Center in Los Angeles on Friday, focusing on the sex-specific autoimmune reactivity to SARS-CoV-2 - the virus which causes Covid-19 - following mildly symptomatic infection.
Read moreOncimmune signs new commercial contracts
21st Dec 2021 13:07
(Sharecast News) - Oncimmune Holdings announced on Tuesday that it has signed further commercial contracts within its 'ImmunoINSIGHTS' pharma services business.
Read moreOncimmune inks deal with global pharma firm
20th Sep 2021 11:24
(Sharecast News) - Immunodiagnostics company Oncimmune has signed an autoantibody profiling agreement with an unnamed global pharmaceutical company, it announced on Monday, to evaluate the autoantibody profiles of patient samples in various autoimmune diseases.
Read moreOncimmune upbeat on three-year lung cancer test study
23rd Aug 2021 15:12
(Sharecast News) - Immunodiagnostics group Oncimmune announced the pre-publication of the three-year follow-up data for the 'Early detection of Cancer of the Lung Scotland' (ECLS) trial on Monday, which showed that after three years, the number of late-stage cancers and deaths were lower in patients tested with the 'EarlyCDT Lung' blood test.
Read moreOncimmune inks research deal with Dana-Farber Cancer Institute
23rd Jul 2021 09:44
(Sharecast News) - Immunodiagnostics group Oncimmune has signed an autoantibody profiling contract with Dana-Farber Cancer Institute, based in Boston, Massachusetts, it announced on Friday.
Read moreOncimmune FY revenues tracking in line with expectations
8th Jun 2021 10:57
(Sharecast News) - Immunodiagnostics group Oncimmune said on Tuesday that 2021 full-year revenues were in line with market expectations,
Read moreOncimmune secures contracts with Roche and Cedars-Sinai
6th Apr 2021 09:14
(Sharecast News) - Immunodiagnostics group Oncimmune said on Tuesday that it had signed two separate agreements for the use of its newly developed and proprietary Infectious Disease panel with Roche Pharmaceuticals and Cedars-Sinai Medical Center.
Read moreOncimmune signs two NHS contracts, has NICE guidance published
14th Dec 2020 14:54
(Sharecast News) - Oncimmune has signed a commercial contract to supply its 'EarlyCDT Lung' blood test to NHS Norfolk & Waveney Clinical Commissioning Group, it announced on Monday.
Read moreOncimmune enters deal with Augmenta to profile plasma samples
11th Nov 2020 10:13
(Sharecast News) - Immunodiagnostics group Oncimmune has signed a new master service agreement with Augmenta Bioworks, it announced on Wednesday, to profile patient plasma samples and characterise therapeutic candidates discovered through Augmenta's 'SingleCyte' and 'DeepGrid' discovery platforms.
Read more